长非编码RNA及其作为炎症性肠病生物标志物的潜在作用
Lorena Ortega Moreno1,2, María Chaparro3, Javier P Gisbert3
1Área Farmacología, Bromatología y Nutrición, Departamento Ciencias Básicas de la Salud, University Rey Juan Carlos (URJC), 28922 Alcorcón, Spain.
International journal of molecular sciences
|August 29, 2024
概括
长非编码RNAs (lncRNAs) 显示出作为炎症性肠病 (IBD) 的非侵入性生物标志物的潜力. 研究正在探索它们在IBD病理生理学中的作用,以改善诊断.
科学领域:
- 胃肠病学 胃肠病学
- 分子生物学分子生物学
- 生物标志物发现发现
背景情况:
- 炎症性肠病 (IBD),包括克罗恩氏病和性结肠炎,是一种慢性炎症状况,全球发病率不断增加.
- 目前在IBD诊断方面的研究强调了对非侵入性和特定生物标志物的需求.
- 长非编码RNAs (lncRNAs) 正在成为各种生物过程中的关键调节者.
研究的目的:
- 审查关于长非编码RNA (lncRNAs) 与炎症性肠病 (IBD) 之间的关联的当前文献.
- 探索lncRNAs作为IBD诊断和管理的非侵入性生物标志物的潜力.
- 为基于lncRNA的IBD生物标志物发现提供未来研究方向的见解.
主要方法:
- 在炎症性肠道疾病的背景下调查lncRNAs的研究的系统文献综述.
- 分析现有关于 lncRNAs 在IBD病理生理学中的作用的数据.
- 评估 lncRNAs 作为非侵入性生物标记物的潜力.
主要成果:
- 长非编码RNAs (lncRNAs) 与炎症性肠病 (IBD) 的复杂病理生理学有关.
- 在初步研究中,特定的 lncRNA 已经显示出作为诊断或预后指标的潜力.
- 检测lncRNAs的非侵入性提供了与当前诊断方法相比的显著优势.
结论:
- 长非编码RNAs (lncRNAs) 是一种有希望的分子类别,用于开发炎症性肠病 (IBD) 的新型非侵入性生物标志物.
- 需要进一步的研究来验证在更大的患者队列中特定的lncRNAs的诊断和预后效用.
- 了解IBD中的lncRNA功能可能会导致更有针对性的治疗策略.
相关概念视频
02:39lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
328
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
328
01:30Inflammatory Bowel Disease II: Crohn's Disease
205
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
205
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
159
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
159
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
01:29Inflammatory Bowel Disease IV: Pharmacological Management
122
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
122